CareLit · DOI-Nachweis · Klinische Pädiatrie
TP53 single nucleotide variants (SNV) in patients developing second malignant neoplasms after treatment for childhood acute lymphoblastic leukemia
DOI 10.1055/s-0036-1582493
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Junk, N Klein, S Schreek, M Zimmermann, A Möricke, K Bleckmann, G Cario, CP Kratz, M Schrappe, M Stanulla
ZeitschriftKlinische Pädiatrie
Ausgabe05/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Today more than 80% of the children with acute lymphoblastic leukemia (ALL) can be cured by application of intensive contemporary treatment regimens [1]. The most severe treatment-related late effects in ALL survivors are second malignant neoplasms (SMN): within 15 years off diagnosis, 1.5 to 2.5% of long-term survivors will develop a SMN, one third of which are therapy-related myeloid neoplasms (t-MN)…
Zitieren
Zitierempfehlung
S Junk, N Klein, S Schreek, M Zimmermann, A Möricke, K Bleckmann, G Cario, CP Kratz, M Schrappe, M Stanulla (2016) TP53 single nucleotide variants (SNV) in patients developing second malignant neoplasms after treatment for childhood acute lymphoblastic leukemia. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0036-1582493
Mit CareLit weiterarbeiten